Atrys is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions, offering diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company provides diagnostic services and medical treatments in Spain, Portugal, and Latin America.
Cyborg Score Rationale
Atrys demonstrates solid market positioning with growing revenue, significant EBITDA expansion, and strategic contracts in Europe and Latin America. However, stock valuation concerns and market cap of $278M suggest room for growth.
Top Insights
Expanding regional presence with new contracts in Spain (Castilla y León, La Rioja) and Chile for diagnostic services
Strong EBITDA growth with 31.7% increase in first nine months of 2024 compared to 2023
Global provider network of 850+ specialist doctors delivering 24/7 remote telemedicine services across multiple countries
Diversified service portfolio spanning radiology, cardiology, ophthalmology, dermatology, and oncology treatment
Named Competitors
Telemedicine & Remote Diagnostics — Digital health platforms competing in remote consultation and diagnostic services
Oncology & Precision Medicine — Competing in precision oncology and cancer treatment services
Recent Developments
(October 2024) Awarded three new contracts for diagnostic services with Spanish regions (Castilla y León, La Rioja) and Chilean public health system
(June 2024) Achieved €107.4 million revenue and €25.3 million adjusted EBITDA in first half of year
(2024) Reported €202 million revenue in 2023 with 27.3% year-over-year growth
Open the full interactive Atrys Health, S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.